A Fifty‐Two–Week, Randomized, Placebo‐Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis

The natural history of nonradiographic axial spondyloarthritis (SpA) is incompletely characterized, and there are concerns that nonsteroidal antiinflammatory drugs provide inadequate disease control in patients with active disease. This study was undertaken to investigate the effects of certolizumab pegol (CZP), an anti–tumor necrosis factor treatment, in patients with nonradiographic axial SpA with objective signs of inflammation.

[1]  M. Dougados,et al.  Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction , 2020, Annals of the Rheumatic Diseases.

[2]  F. Verbraak,et al.  The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW , 2020, RMD Open.

[3]  J. Braun.  Axiale Spondyloarthritis und Psoriasisarthritis , 2020, Zeitschrift für Rheumatologie.

[4]  J. Braun,et al.  [Current treatment of axial spondylarthritis : Clinical efficacy]. , 2020, Zeitschrift fur Rheumatologie.

[5]  M. Ward,et al.  2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis , 2019, Arthritis care & research.

[6]  M. Dougados,et al.  Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA , 2017, Rheumatology.

[7]  A. Bennett,et al.  Should axial spondyloarthritis without radiographic changes be treated with anti-TNF agents? , 2017, Rheumatology International.

[8]  M. Dougados,et al.  2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis , 2017, Annals of the rheumatic diseases.

[9]  R. Landewé,et al.  Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis , 2017, RMD Open.

[10]  A. Chhabra,et al.  Ankylosing Spondylitis and Axial Spondyloarthritis. , 2016, The New England journal of medicine.

[11]  E. Akl,et al.  American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis , 2016, Arthritis & rheumatology.

[12]  M. Dougados,et al.  Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group , 2016, Annals of the rheumatic diseases.

[13]  P. Geborek,et al.  Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients – baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice , 2015, Arthritis Research & Therapy.

[14]  M. Dougados,et al.  A Randomized, Double‐Blind, Placebo‐Controlled, Sixteen‐Week Study of Subcutaneous Golimumab in Patients With Active Nonradiographic Axial Spondyloarthritis , 2015, Arthritis & rheumatology.

[15]  J. Braun,et al.  Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? , 2015, RMD Open.

[16]  R. Landewé,et al.  Brief Report: Calculating the Ankylosing Spondylitis Disease Activity Score If the Conventional C‐Reactive Protein Level Is Below the Limit of Detection or If High‐Sensitivity C‐Reactive Protein Is Used: An Analysis in the DESIR Cohort , 2015, Arthritis & rheumatology.

[17]  L. Gensler,et al.  Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. , 2014, Best practice & research. Clinical rheumatology.

[18]  J. Reveille,et al.  The Concept of Axial Spondyloarthritis: Joint Statement of the Spondyloarthritis Research and Treatment Network and the Assessment of SpondyloArthritis international Society in Response to the US Food and Drug Administration's Comments and Concerns , 2014, Arthritis & rheumatology.

[19]  M. Dougados,et al.  Symptomatic Efficacy of Etanercept and Its Effects on Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: A Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Trial , 2014, Arthritis & rheumatology.

[20]  S. Whittle,et al.  Consensus statement on the investigation and management of non‐radiographic axial spondyloarthritis (nr‐axSpA) , 2014, International journal of rheumatic diseases.

[21]  M. Dougados,et al.  Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study , 2013, Annals of the rheumatic diseases.

[22]  A. Deodhar,et al.  Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study , 2013 .

[23]  J. Braun,et al.  Do patients with non‐radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? , 2012, Arthritis care & research.

[24]  M. Brown,et al.  Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1) , 2012, Annals of the rheumatic diseases.

[25]  J. Sieper,et al.  Referral strategies for early diagnosis of axial spondyloarthritis , 2012, Nature Reviews Rheumatology.

[26]  M. Dougados,et al.  The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general , 2010, Annals of the rheumatic diseases.

[27]  M. Bértolo,et al.  Undifferentiated Spondyloarthritis: A Longterm Followup , 2010, The Journal of Rheumatology.

[28]  D. M. van der Heijde,et al.  ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[29]  M. Dougados,et al.  Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis , 2008, Annals of the rheumatic diseases.

[30]  M. Stone,et al.  Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. , 2005, Arthritis and rheumatism.

[31]  M. Dougados,et al.  Assessment of enthesitis in ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[32]  S P McKenna,et al.  Development of the ASQoL: a quality of life instrument specific to ankylosing spondylitis , 2003, Annals of the rheumatic diseases.

[33]  P. Kind,et al.  Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). , 1997, British journal of rheumatology.

[34]  A. Calin,et al.  A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. , 1994, The Journal of rheumatology.

[35]  A. Calin,et al.  A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. , 1994, The Journal of rheumatology.

[36]  A Calin,et al.  Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. , 1994, The Journal of rheumatology.

[37]  A. Cats,et al.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. , 1984, Arthritis and rheumatism.

[38]  M. Dougados,et al.  Axial spondyloarthritis , 2015, Nature Reviews Disease Primers.

[39]  J. Ware.  SF-36 health survey: Manual and interpretation guide , 2003 .